<DOC>
	<DOCNO>NCT00699764</DOCNO>
	<brief_summary>The purpose study evaluate safety Herpes Simplex candidate vaccine ( gD2t ) adjuvant efficacy prevent genital herpes disease HSV positive negative consort subject genital herpes disease .</brief_summary>
	<brief_title>Safety Herpes Simplex Candidate Vaccine ( gD2t ) With MPL Its Efficacy Prevent Genital Herpes Disease</brief_title>
	<detailed_description>This study monitor Data Safety Monitoring Board At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 45 year age time first vaccination Written inform consent Females childbearing potential must negative pregnancy test enrollment use accepted method birth control The volunteer must regular sexual partner genital herpes disease confirm medical history Any previous history current clinical sign symptom genital herpes disease . Any previous vaccination herpes simplex . Any previous administration MPL . History herpetic keratitis . History erythema multiforme . Female subject pregnant , lactate plan pregnancy one month last vaccine dose . Patient immunocompromised receive immunomodifying therapy kind . Topical corticoid therapy allow . HIV positive time enrollment Clinical sign acute febrile illness time entry study . Any continuous suppressive antiviral oral therapy within 6 month prior entry . Any administration immunoglobulins vaccination course within one month prior first vaccination . Any vaccine administration le one week study vaccination . Previous know hypersensitivity vaccination component vaccine . Simultaneous participation clinical trial investigational compound . Recent history alcoholism drug abuse Recent clinical history evidence significant hepatic disease Recent clinical history evidence renal dysfunction Lifethreatening serious cardiac ( NYHA grade IIIIV ) , gastrointestinal , haematological immunological disorder , opinion investigator , would preclude entry study . Inability unwillingness comply protocol expect complete study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Herpes simplex candidate vaccine</keyword>
	<keyword>Herpes simplex</keyword>
</DOC>